Last updated: 07/17/2024 15:16:20

Co-administration of pneumococcal conjugate vaccine with DTPa-IPV-Hib versus co-administration with DTPa-HBV-IPV/Hib

Request patient level data
GSK study ID
110142
See study documents
Clinicaltrials.gov ID
NCT00652951
See results summary
EudraCT ID
2007-004002-26
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Non-inferiority of co-administration of GSK Biologicals’pneumococcal conjugate vaccine GSK1024850A with DTPa-IPV-Hib versus co-administration with DTPa-HBV-IPV/Hib.
Trial description: The purpose of this trial is to evaluate the immunogenicity and safety of a pneumococcal conjugate vaccine when co-administered with DTPa-IPV-Hib or DTPa-HBV-IPV/Hib in infants as a three-dose primary immunisation course during the first 6 months of life and as a booster dose at 11-12 months of age. The impact of the pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae and H. influenzae in children in their first two years of life will also be assessed. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
Single (Participant)
Allocation:
Randomized
Primary outcomes:

Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) - Primary vaccination

Timeframe: At Month 3, one month after the administration of the third dose of pneumococcal conjugate vaccine

Antibody concentration against protein D (PD) - Primary vaccination

Timeframe: At Month 3, one month after the administration of the third dose of pneumococcal conjugate vaccine

Secondary outcomes:

Number of subjects with antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) ≥ 0.2 μg/mL - Primary vaccination

Timeframe: At Month 3, one month after the administration of the third vaccine dose

Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F - Primary vaccination

Timeframe: At Month 3, one month after the administration of the third vaccine dose

Number of subjects with antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) ≥ 0.2 μg/mL - Primary vaccination.

Timeframe: At Month 3, one month after the administration of the third vaccine dose

Antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) - Primary vaccination

Timeframe: At Month 3, one month after the administration of the third vaccine dose

Opsonophagocytic activity (OPA) titers against pneumococcal cross-reactive serotypes 6A and 19A - Primary vaccination.

Timeframe: At Month 3, one month after the administration of the third vaccine dose

Concentrations of antibodies against diphtheria and tetanus toxoids (anti-D and T) - Primary vaccination

Timeframe: At Month 3, one month after the administration of the third vaccine dose

Anti-polyribosyl-ribitol phosphate (anti-PRP) antibody concentrations - Primary vaccination

Timeframe: At Month 3, one month after the administration of the third vaccine dose

Anti-pertussis toxoid (anti-PT), anti-filamentous haemagglutinin (anti-FHA) and anti-pertactin (anti-PRN) antibody concentrations - Primary vaccination

Timeframe: At Month 3, one month after the administration of the third vaccine dose

Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations - Primary vaccination.

Timeframe: At Month 3, one month after the administration of the third vaccine dose

Anti-polio types 1, 2 and 3 titers - Primary vaccination.

Timeframe: At Month 3, one month after the administration of the third vaccine dose

Number of subjects with antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) ≥ 0.2 μg/mL - Booster vaccination

Timeframe: Prior to (Month 9) and one month after the administration of the booster dose (Month 10)

Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) - Booster vaccination

Timeframe: Prior (Month 9) to and one month after the administration of the booster dose (Month 10)

Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F - Booster vaccination

Timeframe: Prior (Month 9) to and one month after the administration of the booster dose(Month 10)

Number of subjects with antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) ≥ 0.2 μg/mL - Booster vaccination.

Timeframe: Prior (Month 9) to and one month after the administration of the booster dose(Month 10)

Antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) - Booster vaccination

Timeframe: Prior (Month 9) to and one month after the administration of the booster dose (Month 10)

Opsonophagocytic activity (OPA) titers against pneumococcal cross-reactive serotypes 6A and 19A - Booster vaccination.

Timeframe: Prior to (Month 9) and one month after the administration of the booster dose (Month 10)

Concentrations of antibodies against protein D (Anti-PD) - Booster vaccination.

Timeframe: Prior (Month 9) to and one month after (Month 10) the administration of the booster dose

Concentrations of antibodies against diphtheria and tetanus toxoids (anti-D and T) - Booster vaccination.

Timeframe: Prior to (Month 9) and one month after (Month 10) the administration of the booster dose

Anti-polyribosyl-ribitol phosphate (anti-PRP) antibody concentrations - Booster vaccination

Timeframe: Prior to (Month 9) and one month after (Month 10) the administration of the booster dose

Anti-pertussis toxoid (anti-PT), anti-filamentous haemagglutinin (anti-FHA) and anti-pertactin (anti-PRN) antibody concentrations - Booster vaccination.

Timeframe: Prior (Month 9) to and one month after (Month 10) the administration of the booster dose

Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations - Booster vaccination.

Timeframe: Prior (Month 9) to and one month after (Month 10) the administration of the booster dose

Anti-polio types 1, 2 and 3 titers - Booster vaccination.

Timeframe: Prior (Month 9) to and one month after (Month 10) the administration of the booster dose

Number of subjects with booster vaccine response against pertussis toxoid (PT), filamentous haemagglutinin (FHA) and pertactin (PRN) antibodies - Booster vaccination.

Timeframe: One month after (Month 10) the administration of the booster dose

Number of subjects with antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) ≥ 0.2 μg/mL - 12 months after booster dose.

Timeframe: At Month 21, 12 months after the administration of the booster dose (at 23-25 months of age)

Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) - 12 months after booster dose.

Timeframe: At Month 21, 12 months after the administration of the booster dose (at 23-25 months of age)

Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F - 12 months after booster dose.

Timeframe: At Month 21, 12 months after the administration of the booster dose (at 23-25 months of age)

Number of subjects with antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) ≥ 0.2 μg/mL - 12 months after booster dose.

Timeframe: At Month 21, 12 months after the administration of the booster dose (at 23-25 months of age)

Antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) - 12 months after booster dose.

Timeframe: At Month 21, 12 months after the administration of the booster dose (at 23-25 months of age)

Opsonophagocytic activity (OPA) titers against pneumococcal cross-reactive serotypes 6A and 19A - 12 months after booster dose.

Timeframe: At Month 21, 12 months after the administration of the booster dose (at 23-25 months of age)

Concentrations of antibodies against protein D (Anti-PD) - 12 months after booster dose.

Timeframe: At Month 21, 12 months after the administration of the booster dose (at 23-25 months of age)

Number of subjects with positive cultures of Haemophilus Influenzae and/or Streptococcus Pneumoniae in the nasopharynx - Primary vaccination.

Timeframe: One month after the third dose (Month 3), prior to the booster dose (Month 9), 3 months after the booster dose (Month 12), 7 months after the booster dose (Month 16) and 12 months after the booster dose (Month 21)

Number of subjects with positive cultures of Streptococcus Pneumoniae vaccine seroptypes (VS), cross-reactive serotypes (CRS) or other serotypes (OS) in the nasopharynx - Primary vaccination.

Timeframe: One month after the third dose (Month 3), prior to the booster dose (Month 9), 3 months after the booster dose (Month 12), 7 months after the booster dose (Month 16) and 12 months after the booster dose (Month 21)

Number of subjects with acquisition of new Streptococcus pneumoniae and Haemophilus Influenzae strains identified in nasopharyngeal swabs - Primary vaccination.

Timeframe: Prior to the booster dose (Month 9), 3 months after the booster dose (Month 12), 7 months after the booster dose (Month 16) and 12 months after the booster dose (Month 21)

Number of subjects with acquisition of new Streptococcus pneumoniae vaccine serotypes (VS), cross-reactive serotypes (CRS) or other serotypes (OS) identified in nasopharyngeal swabs - Primary vaccination.

Timeframe: Prior to the booster dose (Month 9), 3 months after the booster dose (Month 12), 7 months after the booster dose (Month 16) and 12 months after the booster dose (Month 21)

Number of subjects with solicited local symptoms - Primary vaccination

Timeframe: During the 4-day (Days 0-3) post-vaccination period following each dose and across doses

Number of subjects with solicited general symptoms - Primary vaccination

Timeframe: During the 4-day (Days 0-3) post-vaccination period following each dose and across doses

Number of subjects with unsolicited adverse events (AEs) - Primary vaccination.

Timeframe: Within the 31-day (Days 0-30) post-primary vaccination

Number of subjects with serious adverse events (SAEs)

Timeframe: Throughout the entire study period (up to Month 21)

Number of subjects with solicited local symptoms -Booster vaccination

Timeframe: During the 4-day (Days 0-3) post-vaccination period following booster dose

Number of subjects with solicited general symptoms - Booster vaccination.

Timeframe: During the 4-day (Days 0-3) post-vaccination period following booster dose

Number of subjects with unsolicited adverse events (AEs) - Booster vaccination.

Timeframe: Within the 31-day (Days 0-30) after booster vaccination

Interventions:
  • Biological/vaccine: GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)
  • Biological/vaccine: Infanrix™ hexa.
  • Biological/vaccine: Pediacel™
  • Biological/vaccine: Prevenar™
    • Enrollment:
    780
    Primary completion date:
    2009-12-05
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Van Den Bergh MR et al. (2011) Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial. Pediatr Infect Dis J. 30(9):e170-178.
    Van den Bergh MR et al. (2012) Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) on nasopharyngeal bacterial colonisation in young children: a randomised controlled trial. Clin Infect Dis. 56(3):e30-39. doi: 10.1093/cid/cis922.
    Van Den Bergh MR et al. (2016) Immunogenicity, safety, and reactogenicity of a booster dose of the 10-valent pneumococcal nontypeable H. influenzae protein D conjugate vaccine coadministered with DTPa-IPV-Hib in Dutch children: a randomized controlled trial. Pediatr Infect Dis J. 35(7):e206-219.
    Medical condition
    Infections, Streptococcal
    Product
    GSK1024850A
    Collaborators
    Not applicable
    Study date(s)
    April 2008 to December 2010
    Type
    Interventional
    Phase
    3

    Participation criteria

    Sex
    Female & Male
    Age
    6 - 12 weeks
    Accepts healthy volunteers
    Yes
    • Subjects who the investigator believes that their parents/guardian(s) can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.
    • A male or female between, and including, 6-12 weeks (42-90 days) of age at the time of the first vaccination.
    • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
    • Concurrently participating in another clinical study, at any time during the entire study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
    Inclusion and exclusion criteria
    Inclusion criteria:

      Subjects who the investigator believes that their parents/guardian(s) can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.

      • A male or female between, and including, 6-12 weeks (42-90 days) of age at the time of the first vaccination.
      • Written informed consent obtained from both parents or from the guardian(s) of the subject.
      • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
      • Born after a gestation period of at least 36 weeks.
    Exclusion criteria:

      Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

      • Concurrently participating in another clinical study, at any time during the entire study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
      • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.
      • Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting from one month (30 days) before and up to one month (30 days) after each dose of study vaccine.
      • Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b and/or Streptococcus pneumoniae.
      • Children for whom hepatitis B vaccination is required according to the local recommendations
      • History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b disease.
      • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
      • History of any neurologic disorders or seizures.
      • Acute disease at the time of enrolment.
      • Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination
      • A family history of congenital or hereditary immunodeficiency.
      • Major congenital defects or serious chronic illness.
      • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    HOOFDDORP, Netherlands, 2134 TM
    Status
    Study Complete
    Contact us

    Study documents

    Clinical study report
    Available language(s): English
    Download document(s)
    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Results posted on ClinicalTrials.gov

    Recruitment status
    Study complete
    Actual primary completion date
    2009-12-05
    Actual study completion date
    2010-01-12

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Participate in clinical trial
    Additional information
    Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
    Click here
    Access to clinical trial data by researchers
    Visit website